AU1179000A - Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect - Google Patents

Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect

Info

Publication number
AU1179000A
AU1179000A AU11790/00A AU1179000A AU1179000A AU 1179000 A AU1179000 A AU 1179000A AU 11790/00 A AU11790/00 A AU 11790/00A AU 1179000 A AU1179000 A AU 1179000A AU 1179000 A AU1179000 A AU 1179000A
Authority
AU
Australia
Prior art keywords
txa2
preventives
remedies
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11790/00A
Other languages
English (en)
Inventor
Tsunetoshi Honma
Goro Katsuura
Tatsuro Yagami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of AU1179000A publication Critical patent/AU1179000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU11790/00A 1998-11-19 1999-11-12 Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect Abandoned AU1179000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP32986298 1998-11-19
JP10-329862 1998-11-19
PCT/JP1999/006317 WO2000030683A1 (fr) 1998-11-19 1999-11-12 Composes prophylactiques et/ou therapeutiques destines a des maladies du systeme nerveux central et possedant des composes antagonistes du recepteur de txa2 et/ou inhibiteurs de la txa2 synthase

Publications (1)

Publication Number Publication Date
AU1179000A true AU1179000A (en) 2000-06-13

Family

ID=18226079

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11790/00A Abandoned AU1179000A (en) 1998-11-19 1999-11-12 Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect

Country Status (2)

Country Link
AU (1) AU1179000A (fr)
WO (1) WO2000030683A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1016660B1 (fr) * 1997-09-19 2003-10-29 Shionogi & Co., Ltd. Composes ayant un squelette 2.2.1]bicyclo
EP1295872A4 (fr) * 2000-06-02 2007-05-16 Shionogi & Co Composition medicamenteuse antagoniste pour les recepteurs de pgd2/txa2
JP2002027998A (ja) * 2000-09-29 2002-01-29 Shionogi & Co Ltd 神経細胞変性調節活性の測定方法
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
EP1587473A4 (fr) 2002-12-27 2008-08-13 Novartis Vaccines & Diagnostic Thiosemicarbazones antiviraux et immunostimulants
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
TW200522944A (en) * 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
AU2005265270B2 (en) 2004-06-22 2011-09-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
WO2006018850A2 (fr) * 2004-08-19 2006-02-23 Tel Aviv University Future Technology Development L.P. Compositions et leurs methodes d'utilisation dans le traitement de maladies associees aux amyloides
WO2006027780A2 (fr) 2004-09-08 2006-03-16 Ramot At Tel Aviv University Ltd. Nanostructures peptidiques contenant des peptides modifies par coiffage terminal, et procedes de generation et d'utilisation de celles-ci
US7879212B2 (en) 2005-11-03 2011-02-01 Ramot At Tel-Aviv University Ltd. Peptide nanostructure-coated electrodes
EP2363127A1 (fr) * 2006-01-18 2011-09-07 Evolva SA Modulateurs de PPAR
EP2150111B1 (fr) * 2007-01-18 2016-10-19 Evolva SA 1,3-dioxanes substitués utilisés en tant que modulateurs ppar
US20120142766A1 (en) 2007-11-21 2012-06-07 Evolva Sa Substituted 1,3-dioxanes and their uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1278577C (fr) * 1985-11-18 1991-01-02 Tatsuo Tsuri Derives bicycliques de sulfonamides
AU714312B2 (en) * 1995-06-21 1999-12-23 Shionogi & Co., Ltd. Bicyclic amino derivatives and PGD2 antagonist containing them
US6011019A (en) * 1996-03-12 2000-01-04 University Of South Florida Vasoactive effects and free radical generation by β-amyloid peptides

Also Published As

Publication number Publication date
WO2000030683A1 (fr) 2000-06-02

Similar Documents

Publication Publication Date Title
AU1179000A (en) Preventives and/or remedies for central nervous system diseases containing compounds having TXA2 receptor antagonism and/or TXA2 synthase inhibitory effect
AU2002211612A1 (en) Methods for the treatment of a traumatic central nervous system injury
AU2001282679A1 (en) System for dispensing portions of various substances
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
HUP0202490A3 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU2682395A (en) Crude Drug-Containing Feed
HUP0200819A2 (hu) Sejtméret által szabályozott humán h-sgk gátlóanyagait tartalmazó gyógyszer
AU4060599A (en) Pharmaceutical composition for treating or preventing sleep disorders
HUP0002031A3 (en) Use of benzotiophen derivatives for production pharmaceutical compositions having activity against central nervous system disorders
IL147541A0 (en) Oligonucleotides for inhibiting the expression of human eg5
HUP0003982A3 (en) The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
AU4674797A (en) Phenylalaninol derivatives for the treatment of central nervous system disorders
AU1020201A (en) Human sphingosine kinase gene
HUP0102436A3 (en) Use of reboxetin for preparation of medicament for nervous disorders
AU7788500A (en) Use of substance p antagonists for influencing the circadian timing system
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
WO2000001393A8 (fr) OLIGONUCLEOTIDES INHIBITEURS DE bcl-xL
AU2002227895A1 (en) Sulphonamides for the treatment of central nervous system diseases
IL152688A0 (en) Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system
AU2001280133A1 (en) Preventives and remedies for central nervous system diseases
AU3728099A (en) Specially devised neuronal implants for reconstruction of damaged central nervous system
AU1228499A (en) Application of tnf antagonists as medicaments for treating septic diseases
AU4684099A (en) Oligonucleotides for enhanced modulation of protein kinase expression
AU2001269263A1 (en) Medicaments containing dextrin for treating respiratory disorders such as cysticfibrosis
GR20010300072T1 (en) Use of effectors of the central cholinergic nervous system

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase